Company intelligence / Profile preview

Hopstem Biotechnology

Hangzhou, Zhejiang, Chinahopstem.com ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

Hopstem's lead product hNPC01—an off-the-shelf human forebrain neural progenitor cell therapy derived from GMP-grade iPSCs—is in Phase I clinical trials for chronic ischemic stroke. Preclinical studies showed functional integration and improvement in animal models. The company has additional preclinical programs targeting ALS, Parkinson’s disease, traumatic brain injury, and ocular disorders.

Therapeutic areas: OphthalmologyNeurology
Modalities: Induced pluripotent stem cells (iPSC)-derived cell therapiesNeural progenitor cellsExosomes
Industry: Biotech

Drug pipeline

2 assets

hNPC01

1 more asset in the full pipeline.

Request access →

Partnerships

Neurophth Biotechnology – co-development of iPSC-derived cell therapy for ocular diseases

Beyond the preview

Go deeper on Hopstem Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hopstem Biotechnology.

Explore the full profile